[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cataract\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cataract":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,39,70,99,128,157,183,207,224,241,273,295,313,338,362,383,401,426,458,481,504,527,546,571,589],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100642690","lacrifill-for-ocular-surface-optimization-in-cataract-surgery-100642690",false,"NCT07648095","Lacrifill for Ocular Surface Optimization in Cataract Surgery","Evaluation of Lacrifill™ Canalicular Filler for Optimization of Ocular Surface Parameters and Biometric Precision in Prospective Cataract Surgery Patients With Dry Eye Disease","Inclusion Criteria:\n\n* Age \\>= 40 years\n* Diagnosed dry eye (OSDI \\>= 13, TBUT \\\u003C 10 sec, or Oxford staining \\>= Grade 2)\n* No recent ocular surgeries (\\\u003C6 months)\n* No significant changes in DED regimen within last 1 month\n\nExclusion Criteria:\n\n* Previous punctal plugs or canalicular cautery\n* Active ocular inflammation or corneal pathology unrelated to DED","ALL","40 Years",{"count":20,"type":21},65,"ESTIMATED","OBSERVATIONAL","This is a single-site observational study designed to evaluate the efficacy of Lacrifill™ canalicular filler in optimizing ocular surface parameters and biometric precision in prospective cataract surgery patients with dry eye disease (DED).",[25],"Cataract","RECRUITING","2026-08-20",{"date":29,"type":30},"2026-08-21","ACTUAL",{"date":32,"type":30},"2026-07-22",{"date":34,"type":21},"2027-07-15",{"name":36,"class":37},"The Eye Institute of West Florida","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100648464","corneal-biomechanics-and-surgically-induced-astigmatism-in-pseudoexfoliation-syndrome-100648464","NCT07722247","Corneal Biomechanics and Surgically Induced Astigmatism in Pseudoexfoliation Syndrome","Influence of Corneal Biomechanics on Surgically Induced Astigmatism After Cataract Surgery in Patients With Pseudoexfoliation Syndrome","Inclusion Criteria:\n\n* Adults aged 50-85 years\n* Age-related cataract scheduled for standard phacoemulsification cataract surgery with intraocular lens implantation\n* Presence of pseudoexfoliation syndrome (PEX group) or absence of pseudoexfoliation syndrome (control group)\n* Ability to provide written informed consent\n* Willingness to attend all scheduled postoperative follow-up visits\n\nExclusion Criteria:\n\n* Previous ocular surgery in the study eye\n* Corneal diseases or abnormalities that may affect corneal biomechanical measurements or keratometry\n* Glaucoma and ocular hypertension\n* Ocular trauma or active ocular inflammation","50 Years","85 Years",{"count":49,"type":21},70,"This prospective study aims to evaluate the influence of corneal biomechanical properties on surgically induced astigmatism following standard phacoemulsification cataract surgery in patients with pseudoexfoliation syndrome compared with patients without pseudoexfoliation. Corneal hysteresis (CH), corneal resistance factor (CRF) and corneal astigmatism will be measured before surgery and at postoperative follow-up visits. The relationship between changes in corneal biomechanics and surgically induced astigmatism will be analyzed.",[52,25,53],"Pseudoexfoliation Syndrome","Astigmatism",[55,56,57,58,59,60],"corneal biomechanics","corneal hysteresis","corneal resistence factor","cataract surgery","pseudoexfoliation syndrome","surgically induced astigmatism","2026-08-17",{"date":63,"type":30},"2026-08-18",{"date":65,"type":30},"2026-07-20",{"date":67,"type":21},"2026-10",{"name":69,"class":37},"Kata Culina",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":38},"100610477","surgical-procedure-efficiency-evaluation-study-100610477","NCT07228091","Surgical Procedure Efficiency Evaluation stuDy","Surgical Procedure Efficiency Evaluation stuDy (SPEED): Combination Phaco-Vitrectomy Surgeries With UNITY VCS vs. Constellation in a Real-World Operating Room Setting","Key Inclusion Criteria:\n\n* Able to understand and sign an informed consent form (ICF) that has been approved by an ethics committee.\n* Planned combined phacovitrectomy procedure at one of the selected surgical sites.\n* Planned combined phacovitrectomy procedure with 25-gauge (G) vitrectomy tools.\n\nKey Exclusion Criteria:\n\n* Unplanned\u002Femergency phacovitrectomy.\n* Pregnant.\n* Past history of phacovitrectomy. cataract, vitrectomy in the planned operative eye.\n* Other protocol-defined exclusion criteria may apply.","18 Years",{"count":79,"type":21},180,"The purpose of this real-world evidence study is to compare surgical procedure times for UNITY® VCS and CONSTELLATION® Vision System.",[25,82,83,84,85],"Vitreous Hemorrhage","Retinal Detachment","Macular Pucker","Macular Holes",[87,88],"anterior segment ophthalmic surgery","posterior segment ophthalmic surgery","2026-08-12",{"date":91,"type":30},"2026-08-13",{"date":93,"type":30},"2026-02-09",{"date":95,"type":21},"2027-03",{"name":97,"class":98},"Alcon Research","INDUSTRY",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":47,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":38},"100651000","night-driving-after-trifocal-versus-monofocal-iol-implantation-100651000","NCT07755189","Night Driving After Trifocal Versus Monofocal IOL Implantation","Night-Driving Visual Quality and Visual Disturbances After Bilateral Trifocal Versus Monofocal Intraocular Lens Implantation: A Prospective Observational Cohort Study","TriIOL","Inclusion Criteria:\n\n* Adults aged 18 to 85 years.\n* Scheduled to undergo bilateral phacoemulsification with in-the-bag intraocular lens implantation.\n* Both eyes scheduled to receive the same type and model of either an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens.\n* Possession of a valid motor vehicle driving license.\n* Stable night-driving behavior during the previous 3 months, with night driving occurring at least twice per month.\n* Lens Opacities Classification System III nuclear opalescence grade of 4 or lower in both eyes.\n* Expected intraocular lens power between +10.0 D and +36.0 D, inclusive, in both eyes.\n* Ability to understand the purpose and procedures of the study and independently complete the VND-Q and visual quality questionnaires.\n* Willingness to provide written informed consent and complete the scheduled postoperative follow-up visits.\n\nExclusion Criteria:\n\n* Corneal endothelial cell density below 1,500 cells\u002Fmm² in either eye.\n* History of ocular trauma affecting visual function, previous intraocular surgery, or previous corneal refractive surgery in either eye.\n* Strabismus, amblyopia, or nystagmus in either eye.\n* Any ocular disease that may affect postoperative visual acuity, contrast sensitivity, mesopic visual function, or questionnaire assessment, including but not limited to irregular corneal astigmatism, corneal scar, corneal degeneration, keratoconus, keratitis, corneal dystrophy, uveitis, severe iris atrophy, intraoperative floppy iris syndrome, microphthalmos, macrophthalmos, color vision deficiency, active ocular inflammation, advanced glaucoma or uncontrolled intraocular pressure, macular disease, retinal pigment epithelial disease, diabetic retinopathy, retinal detachment, choroidal detachment, or optic atrophy.\n* A high risk of zonular rupture or an contraindication to in-the-bag intraocular lens implantation, including zonular weakness, zonular dialysis, lens subluxation or dislocation, pseudoexfoliation syndrome, Marfan syndrome, posterior capsule rupture, or cyclodialysis.\n\nSevere or unstable systemic disease, including systemic lupus erythematosus or Sjögren syndrome.\n\n* Use of medication judged by the investigator to increase surgical risk or affect visual function, including amiodarone, chlorpromazine, ethambutol, digitalis, or chloroquine.\n* Requirement for a combined ocular procedure, including limbal relaxing incisions, intraocular drug injection, retinal laser treatment, or another combined procedure judged inappropriate by the investigator.\n* Severe anxiety, depression, or another significant psychiatric disorder.\n* Any other condition judged by the investigator to make participation inappropriate.",{"count":108,"type":21},200,"This prospective observational cohort study will compare night-driving visual difficulty and visual disturbances after bilateral implantation of an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens in adults undergoing cataract surgery. The type of intraocular lens will be selected by each participant and the treating ophthalmologist as part of routine clinical care, and will not be assigned by the investigators.\n\nEligible participants must have a valid motor vehicle driving license and a stable history of night driving during the previous 3 months. The primary outcome will be the total score of the Visual Function and Night Driving Questionnaire (VND-Q) at 3 months postoperatively. Secondary assessments will include glare adaptation, self-rated night-driving quality and driving speed, changes in night-driving behavior, visual disturbances, distance, intermediate and near visual acuity, contrast sensitivity, whole-eye aberrations, pupil diameter, defocus performance, reading speed, spectacle independence, and participant satisfaction.",[25,111],"Presbyopia Correction",[113,114,115,116,117],"Trifocal intraocular lens","Night driving","Visual disturbance","Dysphotopsia","Cataract surgery","NOT_YET_RECRUITING","2026-08-05",{"date":121,"type":30},"2026-08-10",{"date":123,"type":21},"2026-08-30",{"date":125,"type":21},"2031-08-31",{"name":127,"class":37},"Jin Yang",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":38},"100649723","visual-adaptation-and-quality-of-life-after-different-iol-implantation-strategies-100649723","NCT07740590","Visual Adaptation and Quality of Life After Different IOL Implantation Strategies","Evaluation of Visual Adaptation and Optical Performance in Patients With Bilateral Multifocal or Mix-and-Match Intraocular Lens Implantation: A Longitudinal Observational Study","MMAQ-IOL","Inclusion Criteria:\n\n* Age 18 years or older with age-related cataract requiring bilateral phacoemulsification and intraocular lens (IOL) implantation\n* Corneal astigmatism less than 0.75 D\n* Good general health and willing to complete all postoperative follow-up visits\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Previous ocular surgery or ocular trauma\n* Coexisting ocular diseases affecting visual potential, such as corneal opacity, glaucoma, macular degeneration, or diabetic retinopathy\n* Intraoperative or postoperative complications (e.g., posterior capsule rupture)\n* Systemic diseases that may interfere with visual outcomes or follow-up compliance","100 Years",{"count":138,"type":21},264,"This longitudinal observational study aims to evaluate long-term visual adaptation trajectories, optical quality, and patient-reported outcomes in age-related cataract patients following bilateral implantation of multifocal or mix-and-match intraocular lenses (IOLs). Patients will be followed up longitudinally after surgery to systematically assess visual performance and quality of life.",[25,141],"Aphakia - Lens Capsule Present",[143,144,145,146,147],"Intraocular Lenses","Multifocal Intraocular Lenses","Neuroadaptation","Visual Performance","Quality of Life","2026-07-29",{"date":150,"type":30},"2026-07-31",{"date":152,"type":30},"2025-03-01",{"date":154,"type":21},"2027-12-31",{"name":156,"class":37},"Sichuan Academy of Medical Sciences",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100649454","ai-driven-iol-prediction-using-ss-oct-biometry-100649454","NCT07733154","AI-Driven IOL Prediction Using SS-OCT Biometry","International Multicenter Evaluation of a Novel SS-OCT Biometer and Development of an AI-Driven Intraocular Lens Power Prediction Model","Inclusion Criteria:\n\n1. Aged 18 years or above.\n2. Diagnosed with age-related cataract.\n3. Scheduled for routine phacoemulsification with posterior chamber intraocular lens implantation.\n4. Able to cooperate with preoperative ocular biometric measurements and postoperative assessments.\n5. Able to attend the planned 1-month postoperative follow-up visit.\n6. Able to understand the study information and provide written informed consent.\n\nExclusion Criteria:\n\n1. Ocular conditions that may significantly affect biometric measurements or postoperative refractive outcomes, including but not limited to severe corneal disease, severe ocular surface disease, advanced glaucoma, retinal detachment, severe maculopathy, significant optic nerve disease, or ocular trauma.\n2. History of previous intraocular surgery in the study eye, except minor superficial ocular procedures that are not expected to affect ocular biometry or refractive outcomes.\n3. Uncontrolled severe systemic disease that, in the opinion of the investigator or treating clinician, makes the patient unsuitable for routine cataract surgery or study participation.\n4. Cognitive impairment, severe mental disorder, or other condition that prevents the participant from understanding the study or providing valid informed consent.\n5. Poor cooperation that prevents reliable ocular biometric measurement or follow-up assessment.\n6. Current participation in another interventional clinical study that may affect the outcomes of this study.",{"count":165,"type":21},2500,"1 Month","This prospective, multicenter, non-interventional observational study aims to evaluate the agreement between a novel swept-source optical coherence tomography (SS-OCT) biometer and the IOLMaster 700 for ocular biometric measurements and to develop and validate an artificial intelligence (AI)-driven intraocular lens (IOL) power prediction model.\n\nThe primary research questions are:\n\nDoes the novel SS-OCT biometer provide ocular biometric measurements that are comparable to those obtained using the IOLMaster 700? Can an AI-driven IOL power prediction model developed from multicenter biometric, imaging, surgical, and postoperative refractive data improve the accuracy of postoperative refractive prediction?\n\nAdult patients with age-related cataract who are scheduled to undergo routine phacoemulsification with posterior chamber IOL implantation will be consecutively recruited from participating study centers. Participants will undergo routine preoperative clinical assessments together with additional non-contact biometric measurements using the novel SS-OCT biometer before cataract surgery. Cataract surgery and postoperative care will follow standard clinical practice and will not be influenced by the study. Postoperative refractive and visual outcomes at approximately one month after surgery will be collected for analysis. The AI model and research device measurements will be used for research purposes only and will not be used to guide clinical decision-making during the study.",[25],[170,171,172,58,173,174],"Swept-source OCT","ocular biometry","intraocular lens power calculation","axial length","IOLMaster comparison","2026-07-23",{"date":148,"type":30},{"date":27,"type":21},{"date":179,"type":21},"2027-03-31",{"name":181,"class":37},"The Hong Kong Polytechnic University",3,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":194,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":38},"100628958","jasper-robotic-surgical-system-formerly-known-as-the-oryom-robotic-surgical-system-in-cataract-surgery-100628958","NCT07468409","JASPER™ Robotic Surgical System (Formerly Known as the ORYOM™ Robotic Surgical System) in Cataract Surgery","Single-site, Open-label, Prospective Feasibility Study Performed Using the JASPER™ Robotic Surgical System in Cataract Surgery Procedures","Main Inclusion Criteria:\n\n* Patient aged 55 to 80 years\n* Willing and able to sign an informed consent, attend the clinic and comply with all study procedures and the study protocol\n* Patients are scheduled to undergo cataract surgery\n* Clear intraocular media, other than cataract\n* Pupil dilate according to stand of care\n\nMain Exclusion Criteria:\n\n* Prior ocular surgery or trauma in the study eye\n* Polar cataract in the study eye\n* Zonular instability or significant anterior segment abnormalities\n* Active ocular infection or uveitis\n* Pseudoexfoliation (PXF) syndrome in either eye\n* ASA Physical Status Classification \\> 3\n* Participation in another clinical trial within 30 days","55 Years","80 Years",{"count":193,"type":21},40,"INTERVENTIONAL",[196],"NA","This is a prospective, open-label clinical study designed to evaluate the performance and safety of the JASPER™ Robotic Surgical System during cataract surgery.",[25],{"date":200,"type":30},"2026-07-24",{"date":202,"type":30},"2026-02-20",{"date":204,"type":21},"2027-04",{"name":206,"class":98},"ForSight Robotics Ltd",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":38},"100643416","post-refractive-iol-outcomes-with-clareon-truplus-100643416","NCT07610226","Post-refractive IOL Outcomes With Clareon TruPlus","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patients (\\>45 years old) undergoing age-related cataract surgery that previously had myopic corneal refractive surgery.\n* Dominant eye targeted for emmetropia, non-dominant eye may be targeted for ≤-0.75D (mini-monovision).\n* Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20\u002F25) or better in both eyes pre-operatively as determined by surgeon.\n* Normal ocular findings aside from cataract.\n\nExclusion Criteria:\n\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery, except for myopic LASIK or PRK.\n* Previous hyperopic refractive surgery.\n* Corneal HOA ≥1.0 µm (RMS) with OPD at 4mm scan.\n* Any active ocular infection or inflammation.",{"count":214,"type":21},35,"This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.",[25],{"date":175,"type":30},{"date":219,"type":30},"2026-06-25",{"date":221,"type":21},"2027-06-23",{"name":223,"class":37},"Laser Defined Vision",{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":240,"locationsCount":38},"100648309","influence-of-cataract-surgery-on-corneal-biomechanical-properties-in-patients-with-pseudoexfoliation-syndrome-100648309","NCT07719101","Influence of Cataract Surgery on Corneal Biomechanical Properties in Patients With Pseudoexfoliation Syndrome","The Influence of Cataract Surgery on Corneal Biomechanical Properties in Patients With Pseudoexfoliation Syndrome: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* adults aged 50 years and older\n* presence of age-related cataract requiring phacoemulsification cataract surgery\n* presence of pseudoexfoliation syndrome (PEX group) or absence of pseudoexfoliation syndrome (control group)\n* ability and willingness to provide written consent\n\nExclusion Criteria:\n\n* previous ocular surgery,\n* corneal disease,\n* glaucoma or ocular hypertension,\n* dry eye disease (Schirmer test \\\u003C10 mm, tear break-up time \\\u003C5 seconds or positive fluorescein staining),\n* high refractive error (myopia \\> -6.00 D or hyperopia \\> +5.00 D),\n* unilateral pseudoexfoliation when the eye scheduled for surgery showed Adults no signs of PEX,\n* intraoperative or postoperative complications,\n* any ocular disease that could influence corneal biomechanics",{"count":49,"type":21},"Pseudoexfoliation syndrome is associated with alterations in the biomechanical properties of the cornea. This prospective observational cohort study aims to evaluate changes in corneal biomechanical properties after standard phacoemulsification cataract surgery in patients with pseudoexfoliation syndrome compared with patients without pseudoexfoliation syndrome. Corneal hysteresis (CH) and corneal resistance factor (CRF) will be measured using the Ocular Response Analyzer before surgery and at postoperative day 1, day 7, and day 30. The study will enroll patients undergoing routine cataract surgery to compare postoperative changes in CH and CRF between the pseudoexfoliation and control groups.",[52,25],[55,56,235,59,58],"corneal resistance factor","2026-07-21",{"date":175,"type":30},{"date":65,"type":21},{"date":67,"type":21},{"name":69,"class":37},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":194,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":38},"100647921","randomized-controlled-trial-of-the-stein-protocol-a-neuroplastic-pain-education-and-guided-breathing-intervention-during-awake-cataract-surgery-100647921","NCT07715591","Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery","SLin","Inclusion Criteria:\n\nAdults undergoing elective cataract surgery under topical anesthesia who are able to provide informed consent and complete study procedures.\n\nExclusion Criteria:\n\nInability to provide informed consent Inability to comply with study procedures Complex or combined cataract surgery General anesthesia Medical, neurologic, psychiatric, or respiratory conditions interfering with study participation Requirement for modified anesthetic protocols Inability to complete postoperative breathing exercises or follow-up assessments",{"count":249,"type":21},300,[196],"This randomized controlled trial evaluates whether a standardized perioperative neuroplastic intervention: the STEIN Protocol (Strategies and Techniques for Enhancing Integration and Neuroplasticity), consisting of pain neuroscience education, guided imagery, and paced breathing, reduces intraoperative analgesic and anxiolytic requirements.\n\nSecondary outcomes include patient-reported pain, anxiety, satisfaction, and postoperative recovery following cataract surgery.\n\nReduced intraoperative sedative and analgesic requirements may reflect improved patient comfort and autonomic regulation while minimizing medication-related adverse effects.",[25,253],"Cataract (Post-operative Cataract Surgery Follow-up)",[255,256,257,258,259,260,261,262,263,264,265],"Cataract Surgery","Pain Neuroscience Education","Guided Imagery","Guided Breathing","Perioperative Care","Anxiety","Patient Satisfaction","Mind-Body Medicine","Meditation","Breathwrok","Pain",{"date":175,"type":30},{"date":268,"type":30},"2026-06-10",{"date":270,"type":21},"2026-09-01",{"name":272,"class":37},"University of California, Los Angeles",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":194,"phases":283,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100629178","phase-4-toric-performance-and-constant-evaluation-100629178","NCT07471295","Toric Performance And Constant Evaluation","Prospective Assessment of Constant Optimization and Visual Outcomes Following Monofocal Toric IOL Implantation","PACE","Inclusion Criteria:\n\n* Aged 18 years or older;\n* Patients willing, able, and with sufficient cognitive awareness to comply with examination procedures and schedule for follow-up visits;\n* Patients with clinically significant age-related cataract (cataract grades of 1, 2, 3 on the LOCSIII scale, but otherwise healthy, requiring surgical treatment, and scheduled for unilateral or bilateral phacoemulsification or Femtosecond-Laser-Assisted cataract surgery;\n* Patients with existing regular corneal astigmatism of minimum 0.75 D in at least the first eye to be operated.\n* Signed informed consent form;\n* Corrected distance visual acuity projected to be better than 0.2 logMAR after the cataract surgery, as determined by Investigator's medical judgment;\n* Calculated IOL power within the range of the investigational IOL; SE +18.0 D to +28.0 D (0.5 D Steps), and between a Cylinder range of +1.0 D to +2.5 D (0.5 D Steps);\n* Dilated pupil size large enough to visualize TIOL axis markings postoperatively; at least 5.5mm;\n* Clear intraocular media other than cataract.\n\nExclusion Criteria:\n\n* Previous intraocular or corneal surgery in either eye that might confound the outcome of the study or increase the risk to the subject;\n* Keratometric astigmatism (assessed by IOL Master) of minimum 0.75 D in the first eye\n* Traumatic cataract;\n* Pregnancy or lactation;\n* Concurrent participation in another drug or device investigation within the last 30 days;\n* Irregular astigmatism;\n* Instability of keratometry or biometry measurements;\n* Subjects wearing contact lenses as standard vision aid;\n* Abnormal pupil;\n* Any anterior segment pathology that could significantly affect outcomes (e.g. chronic or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.);\n* History of concurrent intraocular inflammation;\n* Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or clinically significant corneal membrane dystrophies);\n* History of any clinically significant retinal or ocular pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus, epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or limit final postoperative visual prognosis;\n* Pseudoexfoliation syndrome (according to investigator judgement);\n* Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment;\n* All kind of infections (acute ocular disease, external \u002F internal infection, systemic infection);\n* Monophthalmic patient;\n* Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus, Parkinson disease\n* Patient expected to require retinal laser treatment before the end of the last follow-up examination;\n* Patient expected to require refractive laser treatment \u002F refractive laser touch-up before the end of the last follow-up examination;\n* Patients who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than Nd:YAG capsulotomy)\n* In case of both eyes included in this trial: Patients who need to undergo surgery on both eyes on the same day",{"count":282,"type":21},130,[284],"PHASE4","The main purpose of this investigation is to support safety and performance assessment of the investigational device with a focus on optimizing the IOL constants based on refractive outcomes.",[25],{"date":32,"type":30},{"date":289,"type":30},"2026-07-13",{"date":291,"type":21},"2028-02-28",{"name":293,"class":98},"Carl Zeiss Meditec AG",6,{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":301,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":194,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":38},"100646329","phase-4-a-prospective-randomized-subject--and-examiner-masked-multicenter-study-comparing-bilateral-clareon-truplus-and-bilateral-clareon-monofocal-intraocular-lens-implantation-spherical-and-toric-in-cataract-subjects-100646329","NCT07693205","A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects","Inclusion Criteria:\n\n1. Adult cataract patients aged ≥22 years scheduled for cataract surgery in both eyes due to visually significant cataracts.\n2. Ability to understand and sign an IRB\u002Fethics committee-approved informed consent form.\n3. Willingness and ability to attend all scheduled study visits as required by the protocol and complete all study testing procedures.\n4. Postoperative potential visual acuity of 20\u002F25 or better in each eye, as determined by the investigator.\n5. Preoperative corneal astigmatism that can be corrected with a T3-T5 toric IOL, or with a spherical IOL plus LRIs\u002FAks, with either resulting in a predicted postoperative astigmatism \\\u003C0.50 D.\n6. IOL power and, if toric, cylinder availability within labeled ranges for the assigned IOL family.\n7. Ability to understand and complete study questionnaires.\n\nExclusion Criteria:\n\n1. Women who are pregnant, planning to become pregnant during the study period, or breastfeeding (by verbal confirmation).\n2. Ocular conditions that could confound study results, including moderate-to-severe corneal pathology, irregular astigmatism, moderate-to-severe dry eye\u002Focular surface disease not optimized, preexisting retinal degenerative disease (e.g., age-related macular degeneration), diabetic retinopathy, or other clinically significant retinal pathology.\n3. Any form of confirmed glaucomatous optic neuropathy or other optic nerve disease expected to affect visual function outcomes.\n4. History of amblyopia, monofixation syndrome, or other binocular vision disorder with poor stereopsis that could confound binocular testing.\n5. Prior ocular surgery (including corneal refractive surgery) in either eye.\n6. Zonular laxity\u002Fdehiscence, pseudoexfoliation with clinically significant zonulopathy, nystagmus, or strabismus that could compromise uncomplicated surgery or reliable visual testing.\n7. Participation in another clinical study (interventional) that could interfere with study results.\n8. Planned monovision\u002Fmini-monovision or desire for monovision targeting.\n9. Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders) per investigator judgment.\n10. Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide reliable self-assessments.\n11. Any active ocular infection or inflammation.","22 Years",{"count":79,"type":21},[284],"This investigator-initiated trial is a prospective, randomized, parallel-group, bilateral implantation study comparing Clareon TruPlus versus Clareon monofocal intraocular lenses (IOLs). Spherical and toric models are permitted in both arms based on standardized preoperative planning and clinical indication. Subjects and postoperative examiners\u002Ftechnicians will be masked to IOL assignment; surgeons will not be masked. The overall structure is modeled after randomized bilateral implantation cataract study designs with a Month 3 primary endpoint visit.",[25],{"date":236,"type":30},{"date":308,"type":30},"2026-06-12",{"date":310,"type":21},"2027-07",{"name":312,"class":37},"Berkeley Eye Center",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":194,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":336,"locationsCount":4},"100647794","oct-pro-model-vs-clinicians-cataract-surgery-outcome-prediction-100647794","NCT07713069","OCT-PRO Model vs. Clinicians: Cataract Surgery Outcome Prediction","A Randomized Controlled Trial Comparing the Accuracy of the Postoperative Vision Prediction Model for Cataract Surgery (OCT-PRO) With Clinicians' Predictions of Surgical Outcomes","Inclusion Criteria:\n\n* Age ≥18 years scheduled to undergo phacoemulsification with intraocular lens (Phaco+IOL) implantation.\n* Outpatient diagnosis of senile, complicated, or metabolic cataract.\n* For bilateral cataracts, the eye with more advanced disease will be included.\n\nExclusion Criteria:\n\n* History of amblyopia or neuro-ophthalmic disease in the operative eye.\n* Poor-quality OCT images precluding clear visualization of fundus structures.\n* Previous intraocular surgery in the operative eye.\n* Hearing or intellectual impairment preventing adequate cooperation.","90 Years",{"count":322,"type":21},534,[196],"Cataract is the leading cause of blindness worldwide, yet 5-20% of patients fail to achieve satisfactory visual recovery after surgery. Current methods for predicting postoperative visual acuity lack accuracy, particularly in patients with co-morbid fundus diseases. The OCT-PRO model, developed by our team, uses artificial intelligence (AI) to integrate optical coherence tomography (OCT) images and clinical data to forecast surgical outcomes. This multi-center, randomized, single-blind trial aims to compare the predictive accuracy of OCT-PRO-assisted predictions versus standard clinician predictions. A total of 534 participants will be randomized 1:1 to either the experimental group (OCT-PRO-assisted prediction) or the control group (routine care). The primary outcome is the mean absolute error (MAE) between predicted and actual postoperative best-corrected visual acuity (BCVA). Secondary outcomes include patient satisfaction, informed decision-making scores, and clinician acceptance of the AI tool. This study will provide high-level evidence on the clinical utility of AI in optimizing cataract surgical decision-making and patient communication.",[25],[25,327,328,329,330],"Post-operative prognosis","Artificial intelligence","Multimodal data fusion","Clinical decision support","2026-07-17",{"date":65,"type":30},{"date":65,"type":21},{"date":335,"type":21},"2026-12-31",{"name":337,"class":37},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":17,"minAge":345,"maxAge":191,"enrollmentInfo":346,"targetDuration":4,"studyType":194,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":4},"100647830","clinical-trial-on-the-visual-function-of-enhanced-monofocal-and-edof-intraocular-lenses-100647830","NCT07715071","Clinical Trial on the Visual Function of Enhanced Monofocal and EDoF Intraocular Lenses","Randomized Clinical Trial to Evaluate the Visual Function of Enhanced Monofocal and Extended Depth of Field Intraocular Lenses","INCLUSION CRITERIA:\n\n* Patients with bilateral cataracts at different stages of development.\n* Patients with functional visual demands.\n* Age between 45 and 80 years.\n* Male or female sex.\n* Ability to provide informed consent.\n\nEXCLUSION CRITERIA:\n\nPreoperative Exclusion Criteria\n\n• Medical criteria:\n\nCorneal astigmatism greater than 1.0 diopter. Pre-existing ocular pathology. Previous refractive surgery. Previous corneal or intraocular implant. Poor general health status or potentially reduced neuroadaptation capacity due to previous stroke, Alzheimer's disease, other forms of dementia, etc.\n\nUnrealistic postoperative visual expectations.\n\nIntraoperative Withdrawal Criteria\n\n* Vitreous loss.\n* Pupillary trauma.\n* Factors likely to affect the medium-term performance of the intraocular lens: Zonular damage, Capsulorhexis tear or injury, Capsular rupture, Endothelial damage.","45 Years",{"count":347,"type":21},90,[196],"Randomized clinical trial to evaluate the visual performance of enhanced monofocal and extended depth-of-field intraocular lenses",[25],[352,25,353,354],"Intraocular lens","Enhanced monfocoal IOL","EDoF IOL","2026-07-15",{"date":65,"type":30},{"date":358,"type":21},"2026-09-21",{"date":179,"type":21},{"name":361,"class":37},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":194,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":38},"100646213","evaluation-of-visual-outcomes-complications-and-neuroadaptation-following-bilateral-implantation-of-envista-envy-trifocal-intraocular-lenses-100646213","NCT07696130","Evaluation of Visual Outcomes, Complications, and Neuroadaptation Following Bilateral Implantation of enVista Envy Trifocal Intraocular Lenses","Inclusion Criteria:\n\n* Bilateral cataract or refractive lens exchange candidates.\n* Presbyopia and\u002For hyperopia.\n* Preoperative corneal astigmatism less than 1.00 diopter (D).\n* Absence of ocular diseases other than cataract.\n* High motivation to achieve spectacle independence.\n* Patients willing to accept the possibility of mild photic phenomena, such as glare and halos.\n\nExclusion Criteria:\n\n* Ocular Conditions:\n\n  * Glaucoma.\n  * Amblyopia.\n  * Macular diseases (including macular degeneration and other macular pathology).\n  * Angle kappa greater than 0.5 mm.\n  * Dry eye disease.\n  * Corneal disorders.\n  * Pupil abnormalities.\n  * Irregular astigmatism.\n  * Ocular motility disorders or strabismus.\n  * Pupil diameter \\\u003C 2.5 mm under photopic conditions or \\> 6.0 mm under mesopic conditions.\n  * Abnormalities of the capsular bag or zonular apparatus, including pseudoexfoliation syndrome (PEX).\n* Lifestyle Factors:\n\n  * Patients with unrealistic expectations regarding postoperative visual outcomes.\n  * Individuals whose professions require highly precise visual performance, such as pilots, professional drivers, architects, or similar occupations.\n  * Patients satisfied with using spectacles for near vision.\n  * Age greater than 75 years (due to potential difficulties with neuroadaptation to new visual conditions).\n* Psychological and Personality Factors:\n\n  * Patients with psychiatric disorders that may interfere with study participation or outcome assessment.\n  * Patients dissatisfied with progressive addition lenses (progressive spectacles).\n  * Patients with dyslexia or a history of stroke.\n  * Type A personality traits (perfectionists).\n* Patients will also be excluded if the calculated IOL power falls outside the available range of +6.00 D to +34.00 D or if they have a history of laser vision correction surgery.","75 Years",{"count":370,"type":21},20,[196],"The enVista Envy intraocular lens (IOL) manufactured by Bausch + Lomb is a new multifocal intraocular lens based on diffractive optics. It was registered with the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in September 2025. The lens also bears the CE mark, indicating that it is approved for marketing and use within the European Union.\n\nIts innovative design is based on a smooth, continuous transition between diffractive rings, allowing patients to achieve excellent visual quality at far, intermediate, and near distances while reducing the incidence and severity of unwanted photic phenomena such as glare and halos. Thanks to this technology, patients may achieve better uncorrected visual acuity, reduced dependence on spectacles, and faster neuroadaptation.\n\nThe Second Department of Ophthalmology is the first center in Poland to be offered participation in a clinical study evaluating the safety and effectiveness of the enVista Envy IOL. The planned study will provide the first clinical experience with this lens in Poland and contribute to expanding knowledge regarding modern intraocular lens technologies.\n\nTwenty patients will be selected according to predefined inclusion and exclusion criteria. Preoperative assessment will include a comprehensive ophthalmic examination and IOL power calculation. Cataract surgery will be performed using bimanual MICS (Micro-Incision Cataract Surgery) phacoemulsification. Surgery in the fellow eye will be performed one month after the first procedure.\n\nBefore surgery and during follow-up visits at 1, 3, and 6 months postoperatively, the following assessments will be performed: routine ophthalmic examination, intraocular pressure (IOP) measurement, visual evoked potentials (VEP), monocular and binocular uncorrected distance visual acuity (UDVA), distance best-corrected visual acuity (DBCVA) at 4 meters, intermediate visual acuity (66 cm) and near visual acuity (40 cm), both corrected and uncorrected, monocularly and binocularly (logMAR charts), binocular contrast sensitivity testing, and defocus curve assessment.\n\nIntraoperative and postoperative complications, quality of vision (using the standardized Quality of Vision Questionnaire \\[QoV\\] and the Near Activity Vision Questionnaire \\[NAVQ\\]), speed of neuroadaptation, spectacle independence, and the occurrence of photic phenomena such as glare and halos will also be analyzed.",[25,253],"2026-07-08",{"date":376,"type":30},"2026-07-10",{"date":378,"type":30},"2026-02-01",{"date":380,"type":21},"2029-02",{"name":382,"class":37},"Pomeranian Medical University Szczecin",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":301,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":194,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":399,"locationsCount":400},"100638560","clinical-evaluation-of-a-novel-trifocal-iol-100638560","NCT07587138","Clinical Evaluation of a Novel Trifocal IOL","Key Inclusion Criteria:\n\n* The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to \"0.0\" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery.\n* Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D).\n* In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20\u002F32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes.\n* Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk.\n* People who want to have one eye set for distance vision and the other for near vision.\n* The doctor expects significant blurry vision (astigmatism) after the procedure.\n* Other protocol-specified exclusion criteria may apply.",{"count":390,"type":21},66,[196],"The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.",[394,25],"Aphakia","2026-07-07",{"date":374,"type":30},{"date":67,"type":21},{"date":310,"type":21},{"name":97,"class":98},4,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":407,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":194,"phases":410,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":38},"100646235","a-study-on-the-application-of-smart-bed-exit-alert-assistive-devices-for-detecting-preoperative-bed-exits-in-ophthalmic-surgery-patients-in-the-operating-room-100646235","NCT07693829","A Study on the Application of Smart Bed-Exit Alert Assistive Devices for Detecting Preoperative Bed Exits in Ophthalmic Surgery Patients in the Operating Room","Inclusion Criteria:\n\n* Patients undergoing cataract surgery.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Unable to follow verbal instructions.",true,{"count":409,"type":21},160,[196],"This prospective, randomized interventional study aims to evaluate the effectiveness of a smart bed-exit alert system for patients undergoing cataract surgery during the preoperative waiting period. Participants will be randomly assigned to either the smart bed-exit alert system group or the standard care group. The study will compare nurse bedside visit frequency and nursing care time during the preoperative waiting period to evaluate whether the smart bed-exit alert system improves patient safety and nursing care efficiency.",[25],[414,415,416,417,255],"Smart Bed-Exit Alert System","Patient Safety","Pressure Sensor","Nursing Efficiency","2026-07-03",{"date":420,"type":30},"2026-07-09",{"date":422,"type":30},"2026-04-23",{"date":335,"type":21},{"name":425,"class":37},"National Taiwan University Hospital",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":407,"sex":17,"minAge":433,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":436,"conditions":437,"keywords":442,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":38},"100646171","survey-of-sensory-impairment-indicators-among-adults-aged-65-years-and-older-in-xinxing-county-100646171","NCT07694505","Survey of Sensory Impairment Indicators Among Adults Aged 65 Years and Older in Xinxing County","A Cross-Sectional Survey of Global Priority Sensory Impairment Indicators Among People Aged 65 Years and Older in Xinxing County","Inclusion Criteria:\n\n1. Aged 65 years or older.\n2. Voluntarily participates in the study and provides signed informed consent.\n\nExclusion Criteria:\n\n1. Unable to cooperate with study-related examinations, including because of disability, communication barriers, or other reasons.\n2. Has severe systemic disease that may affect study examinations or make participation potentially hazardous to health.\n3. Considered by the investigator to be unsuitable for participation in the study.","65 Years",{"count":435,"type":21},2854,"This cross-sectional population-based survey will be conducted among residents aged 65 years and older in Xinxing County, Yunfu, Guangdong Province, China. The study will use standardized eye examinations, visual acuity and refractive assessment, anterior segment examination, hearing screening and questionnaires to estimate effective refractive error coverage, effective cataract surgical coverage, effective hearing technology coverage, common eye disease status, and dual sensory impairment among older adults. The findings are intended to provide evidence for primary-level eye and hearing health services.",[438,439,440,25,441],"Visual Impairment","Hearing Loss","Dual Sensory Impairment","Refractive Error",[443,444,445,446,447,448,449,450,451],"Effective refractive error coverage","Effective cataract surgical coverage","Effective hearing technology coverage","Older adults","Population-based survey","Cross-sectional study","SENSIIS","WHOears","Xinxing County","2026-07-02",{"date":376,"type":30},{"date":455,"type":21},"2026-07-06",{"date":335,"type":21},{"name":337,"class":37},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":194,"phases":467,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":38},"100646637","prospective-randomized-parallel-group-comparison-of-two-refractive-edof-intraocular-lenses-johnson--johnson-tecnis-puresee-versus-1stq-comfort-z-edof-100646637","NCT07688681","Prospective, Randomized, Parallel-group Comparison of Two Refractive EDOF Intraocular Lenses: Johnson & Johnson Tecnis PureSee Versus 1stQ Comfort Z-EDOF","1stQvsPureSee","Inclusion Criteria:\n\n* Age ≥40 years, able to understand the study and give written informed consent\n* Clinically significant bilateral age-related cataract suitable for phacoemulsification with posterior chamber IOL implantation\n* Expected postoperative best-corrected visual acuity ≤0.2 logMAR in both eyes\n* Regular corneal astigmatism ≤4.5 D in both eyes (IOLMaster 700)\n* Axial length 21.5-26.5 mm in both eyes\n* Clear cornea without clinically significant opacities, scars, or stromal dystrophies\n* Normal pupil function; no significant anisocoria (≥1 mm) and no afferent pupillary defect\n* Acceptance of the target refraction strategy: emmetropia in the dominant eye and -0.50 D in the non-dominant eye\n* Willing and able to attend all follow-up visits (Month 1, 3, and 6)\n* Written informed consent obtained before any study-related procedure\n\nExclusion Criteria:\n\n* Prior corneal refractive surgery, corneal transplantation, glaucoma filtering surgery, or vitreoretinal surgery in either eye (uncomplicated intravitreal injections allowed)\n* Irregular astigmatism, keratoconus, forme fruste keratoconus, corneal ectasia, significant corneal opacities or scars, or endothelial dystrophy\n* Keratometric astigmatism \\>4.5 D in either eye\n* Axial length \\\u003C21.5 mm or \\>26.5 mm in either eye\n* Calculated IOL power outside the available range of either study lens\n* Macular pathology expected to limit visual acuity (e.g., age-related macular degeneration, diabetic maculopathy, epiretinal membrane, macular hole)\n* Advanced glaucoma with central visual field involvement, or IOP not controlled on ≤2 topical medications\n* Optic neuropathy expected to limit visual potential\n* Pre-existing amblyopia in either eye\n* Significant anisocoria, afferent pupillary defect, non-dilating pupil, or iris abnormalities affecting IOL function or measurement\n* Endothelial cell density \\\u003C1500 cells\u002Fmm²\n* Uncontrolled diabetes mellitus (HbA1c \\>9%) or autoimmune disease with active ocular involvement\n* Systemic medications affecting pupil size that cannot be discontinued (e.g., tamsulosin)\n* Pregnancy or breastfeeding\n* Intraoperative complication precluding safe in-the-bag IOL implantation (affected eyes withdrawn)\n* Cognitive impairment, language barrier, or other factors preventing reliable participation\n* Current enrollment in another interventional clinical study affecting visual outcomes",{"count":466,"type":21},110,[196],"This study compares two types of artificial lens (intraocular lens, or IOL) used during cataract surgery. Both are extended depth-of-focus (EDOF) lenses, designed to give clear vision across a range of distances - far and intermediate - so that people depend less on glasses after surgery. The two lenses, the Tecnis PureSee and the 1stQ Comfort Z-EDOF, use different optical designs, and it is not yet known whether one provides a wider range of clear vision than the other.\n\nAdults having cataract surgery in both eyes may take part. Each participant is randomly assigned to receive one of the two lens types, and the same lens type is implanted in both eyes. Neither the participant nor the staff measuring vision knows which lens was used until the main 6-month assessment is complete.\n\nAfter surgery, participants attend check-ups at 1, 3, and 6 months. The study measures how wide a range of distances each person can see clearly, along with vision at different distances, quality of vision, side effects such as glare or halos, and overall satisfaction. The results will help doctors and patients choose between these lens types.",[25],[471],"EDOF intraocular lens","2026-06-30",{"date":395,"type":30},{"date":475,"type":21},"2026-08-01",{"date":477,"type":21},"2029-04-01",{"name":479,"class":480},"Vienna Hospital Association","OTHER_GOV",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":38},"100644657","small-rna-trf-31-changes-in-patients-with-age-related-cataract-100644657","NCT07672899","Small RNA tRF-31 Changes in Patients With Age-Related Cataract","Biphasic Dynamics of the tRNA-derived Small RNA tRF-31 Set the Lens Oxidative Survival Threshold by Restraining HIPK2-mediated Dual-track Lethality in Age-related Cataract","Inclusion Criteria:\n\nPatients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written informed consent.\n\nExclusion Criteria:\n\nHistory of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.",{"count":108,"type":21},"The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31\u002FHIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.",[25],[492,493,494],"age-related cataract","oxidative stress","tRNA-derived small RNA","2026-06-23",{"date":497,"type":30},"2026-06-29",{"date":499,"type":30},"2026-06-17",{"date":501,"type":21},"2026-09-16",{"name":503,"class":37},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":320,"enrollmentInfo":511,"targetDuration":4,"studyType":194,"phases":512,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":4},"100643626","effects-of-oxygen-cage-support-during-cataract-surgery-100643626","NCT07632326","Effects of Oxygen Cage Support During Cataract Surgery","The Effect of Oxygen Support Cage Material Use During Cataract Surgery on Operation Time, Anxiety, Physiological Parameters, and Patient Experiences: A Mixed Methods Study","Inclusion Criteria\n\n* Willing to participate in the study voluntarily and provides informed consent\n* Aged 18 years or older\n* Having no hearing or cognitive impairments\n* Undergoing cataract surgery for the first time Exclusion Criteria\n* Conversion from local anesthesia to general anesthesia during the surgery\n* Patient's non-participation or refusal to complete the anxiety assessment during the surgery",{"count":49,"type":21},[196],"Cataract is an ocular disorder resulting from lens opacity; it stands as the most common cause of preventable blindness worldwide and significantly impairs the quality of life in elderly individuals. Surgical treatment utilizing small-incision phacoemulsification is the most effective solution for cataracts. Cataract surgery is generally performed under local anesthesia, which requires patients to remain awake throughout the operation, thereby potentially increasing their anxiety experiences. Elevated anxiety not only reduces patient comfort but can also lead to alterations in physiological parameters and a prolongation of the operation time. Furthermore, it is observed that the surgical drapes used to maintain the sterility of the surgical field during the operation cause discomfort to the patient. The weight and positioning of these drapes can cover the patient's mouth and nose area during the ongoing surgery, creating a sensation of difficulty in breathing (dyspnea). In addition to these circumstances, standard oxygen support is provided to the patient during cataract surgery performed under local anesthesia. This support is administered nasally via an open-ended oxygen tubing from beneath the surgical drape, aiming to ease the patient's respiration. However, when the oxygen flow rate is increased based on the patient's needs, high-velocity and high-concentration oxygen administration is observed to cause mucosal dryness, which shortly triggers reflex-induced irritative coughing attacks. For these reasons, it is crucial to keep anxiety under control, provide oxygen to prevent hypoxia, and monitor physiological parameters during cataract surgery.",[25],[255,516,260,517,518],"Oxygen Support","Patient Experience","Surgical Nursing",{"date":520,"type":30},"2026-06-26",{"date":522,"type":21},"2026-07-01",{"date":524,"type":21},"2027-05-01",{"name":526,"class":37},"Ataturk University",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":38},"100641197","clareon-truplus-vs-tecnis-eyhance-iols-in-cataract-patients-100641197","NCT07658040","Clareon TruPlus vs Tecnis Eyhance IOLs in Cataract Patients","Visual and Patient Reported Outcomes Comparing Clareon TruPlus IOL and Tecnis Eyhance IOLs in Normal Cataract Patients: Stage 1","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patient diagnosed with age-related cataracts bilaterally.\n* Planned bilateral cataract removal and with bilateral implantation of the Clareon TruPlus IOL\u002FToric BLF (T3-T5) or Tecnis Eyhance IOL\u002FEyhance Toric (equivalent to T3-T5).\n* Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20\u002F25) or better in both eyes postoperatively as determined by surgeon.\n* Residual astigmatism expected to be \\\u003C= 0.50 diopters in both eyes postoperatively as determined by surgeon (After using either toric IOL or arcuate incision with laser or manual LRI).\n* Normal ocular findings aside from cataract.\n\nExclusion Criteria:\n\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery including corneal refractive surgery.\n* History of amblyopia or monofixation syndrome with poor stereoscopic vision.\n* Participants desiring monovision.\n* Any planned simultaneous\u002Fcombined procedures at time of cataract surgery (e.g. MIGs).\n* Participation in another clinical study that could interfere with the results.\n* Any active ocular infection or inflammation.",{"count":49,"type":21},"This study is a prospective, randomized, two-arm, single-center, single-surgeon, double-masked (subject and assessor) comparative study. It involves bilateral implantation of intraocular lenses (IOLs), comparing Clareon TruPlus IOL and Tecnis Eyhance IOLs in normal cataract patients. The study will be conducted at one site and will include a pre-operative visit and a 3-month post-operative assessment.",[25],"2026-06-16",{"date":539,"type":30},"2026-06-18",{"date":541,"type":21},"2026-08-09",{"date":543,"type":21},"2027-08-09",{"name":545,"class":37},"Gainesville Eye Associates",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":194,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":38},"100641136","effect-of-dry-eye-treatment-on-corneal-astigmatism-measurements-100641136","NCT07657858","Effect of Dry Eye Treatment on Corneal Astigmatism Measurements","Effect of Dry Eye and Ocular Surface Treatment on Agreement and Repeatability of Corneal Astigmatism Measurements Among Three Devices","Inclusion Criteria:\n\n* Patients with age-related cataract undergoing preoperative ocular examination.\n* Ability to complete ocular surface evaluation, including the Ocular Surface\n* Disease Index questionnaire, non-invasive tear film break-up time, tear meniscus height, Schirmer test, and ocular surface staining.\n* Ability to complete repeated corneal astigmatism measurements using IOLMaster 700, Pentacam AXL, and iTrace Prime.\n* Ability to maintain stable fixation during device measurements. Provision of written informed consent.\n\nExclusion Criteria:\n\n* Previous ocular surgery or ocular trauma.\n* Corneal degeneration, corneal dystrophy, or other corneal diseases that could affect corneal measurements.\n* Active corneal or conjunctival infection.\n* Uveitis.\n* Use of any topical eye drops within 24 hours before examination.\n* Use of antiglaucoma medications.\n* Contact lens wear within 1 month before examination.\n* Previous or ongoing treatment for dry eye disease.\n* Poor fixation during device measurements.\n* Poor-quality measurements from any study device",{"count":554,"type":21},400,[196],"This prospective single-center study evaluates the effect of dry eye disease and short-term ocular surface treatment on the agreement and repeatability of corneal astigmatism measurements in patients with age-related cataract. Participants undergoing preoperative cataract evaluation are classified into a control group or a dry eye disease group according to ocular surface symptoms and objective tear film findings.\n\nAll participants undergo ocular surface assessment and repeated corneal measurements using three commonly used devices: IOLMaster 700, Pentacam AXL, and iTrace Prime. Measurements include keratometric corneal astigmatism, total corneal astigmatism, and vector components of astigmatism. Patients with dry eye disease receive 0.3% sodium hyaluronate eye drops four times daily for 2 weeks, after which ocular surface assessment and device measurements are repeated.\n\nThe primary objective is to determine whether dry eye disease reduces interdevice agreement and test-retest repeatability of corneal astigmatism measurements, and whether short-term ocular surface treatment improves measurement stability. Interdevice agreement is assessed using Bland-Altman analysis, and repeatability is evaluated using within-subject standard deviation, test-retest repeatability, and intraclass correlation coefficient.",[558,25],"Dry Eye",[560,25,561,562,563],"Dry Eye Disease","Corneal Astigmatism","Ocular Surface",";Biometry","2026-06-15",{"date":539,"type":30},{"date":567,"type":30},"2026-01-01",{"date":569,"type":21},"2030-12-31",{"name":127,"class":37},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":38},"100642852","visual-and-patient-reported-outcomes-with-clareon-truplus-100642852","NCT07648355","Visual and Patient Reported Outcomes With Clareon TruPlus","Visual and Patient Reported Outcomes of Clareon TruPlus IOL in Cataract Surgery Patients","Inclusion Criteria:\n\n* Willing and able to understand and sign informed consent.\n* Adult patients (\\>40 years old) undergoing age-related cataract surgery with expected best-corrected visual outcomes of 20\u002F25 or better in both eyes pre-operatively as determined by surgeon and with regular corneal astigmatism correctable to less than 0.75 diopters post-operatively with no more than a T6 toric power IOL.\n* Normal ocular findings aside from cataract and mild dry eye.\n\nExclusion Criteria:\n\n* Subjects targeted for monovision.\n* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, amblyopia, zonular laxity or dehiscence, pseudoexfoliation.\n* Previous history of any ocular surgery including LASIK (excluding minor lid procedures).\n* Patients with irregular astigmatism\u002Ftopography, corneal dystrophies, and pupil abnormalities.\n* Participation in another clinical study that could interfere with the results.\n* Any active ocular infection or inflammation.",{"count":193,"type":21},"This is a prospective, single-site, two-surgeon, single-arm, observational study evaluating the Clareon TruPlus IOL. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the IOLSAT Questionnaire.",[25],"2026-06-09",{"date":564,"type":30},{"date":584,"type":30},"2026-06-02",{"date":586,"type":21},"2027-07-11",{"name":588,"class":37},"OVO LASIK + Lens",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":407,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":598,"conditions":599,"keywords":615,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":38},"100643686","development-of-a-mobile-terminal-based-intelligent-detection-system-for-multiple-anterior-segment-diseases-of-the-eye-100643686","NCT07634913","Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye","LENS","Inclusion Criteria:\n\n* Adults aged 18 years or older;\n* Willing to participate and able to provide written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Unable to cooperate with anterior segment image capture (including smartphone-based photography or slit-lamp biomicroscopy).",{"count":597,"type":21},3000,"This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening. The system is designed to identify 16 clinically important anterior segment conditions from images captured using a standard Android smartphone. A core design feature of the system is that all image analysis is performed entirely on the smartphone itself, without requiring internet connectivity or cloud-based server infrastructure.\n\nThe study is motivated by a structural challenge in the deployment of medical AI: systems that depend on cloud infrastructure for inference are non-functional in settings without reliable internet access, which disproportionately excludes populations in low-resource regions where the burden of preventable eye disease is highest. This study evaluates whether an on-device AI system, designed with operational constraints as a primary engineering objective, can deliver clinically acceptable diagnostic performance while remaining operable under real-world connectivity limitations.\n\nThe study comprises five evaluation components. First, the diagnostic performance of the AI system is benchmarked against board-certified ophthalmologists of varying seniority on a standardized set of smartphone-captured anterior segment images. Second, the usability of the system is evaluated among non-medical users who perform self-administered screening with minimal instruction, with per-screening time recorded across consecutive attempts to characterize the learning curve. Third, a head-to-head field trial directly compares the on-device AI system against a functionally equivalent cloud-based deployment of the same model architecture across key operational dimensions including screening duration, diagnostic performance, and user acceptability. Fourth, population-level screening is conducted among consecutively enrolled community residents at two low-resource sites, with per-disease sensitivity and specificity calculated against reference-standard slit-lamp examinations. Fifth, pre-specified health-economic and environmental analyses compare the two deployment modalities in terms of per-person screening cost, cost-effectiveness, per-inference electricity consumption, and projected carbon emissions at scale.\n\nThe reference standard for all diagnostic comparisons is slit-lamp biomicroscopic examination performed by board-certified ophthalmologists. The study is designed and reported in accordance with the DECIDE-AI reporting guideline for early-stage clinical evaluation of AI-driven decision-support systems.",[600,25,601,602,603,604,605,606,607,608,609,610,611,612,613,614],"Artifical Intelligence","Pterygium","Keratopathy","Subconjunctival Hemorrhage","Conjunctivitis","Stye","Blepharitis","Entropion","Ectropion","Exophthalmos","Irregular Pupils","Conjunctival Concretions","Hyphema","Hypopyon","Corneal Transplant Status",[616,617,618,619],"Artificial Intelligence","Standalone Deployment","Smartphone","Eye Disease Screening","2026-06-08",{"date":581,"type":30},{"date":623,"type":30},"2023-12-12",{"date":625,"type":21},"2028-12",{"name":337,"class":37}]